Novel Combination Therapies for Untreated Multiple Myeloma
|
|
- Sophia York
- 5 years ago
- Views:
Transcription
1 Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201
2 Disclosures 2 Employee Consultant Major Stockholder Speakers Bureau Honoraria Advisory Board None Bristol-Myers Squibb, Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals None Celgene Bristol-Myers Squibb, Celgene, Millennium, Onyx Bristol-Myers Squibb, Millennium Pharmaceuticals, Onyx Pharmaceuticals Presentation may include agents that are not yet approved, and agents used for unapproved indications
3 Current Paradigm of Initial Treatment 3 Transplant eligibility Transplant Candidates Autotransplant Consolidation Initial therapy or Maintenance Continue initial therapy Non-transplant Candidates
4 4 Initial Treatment of Transplant Candidates Autotransplant Consolidation Initial therapy Maintenance Conventional VAD Novel Combinations 2-Drug: TD, VD, RD, Rd 3-Drug/1-Novel: TAD, PAD, VDD, CVD 3-Drug/2-Novel: VTD, RVD 4-Drug/2-Novel: CVDR, VTDC, RVDD
5 Pre-transplant Induction Response Rates Composite Response Rates 50-60% 15-18% VGPR 60-75% 30-40% PR % 40-60% VAD 2-Drug 3-Drug 4-Drug 1. Lokhorst et al. Blood 2010;115(6): Harousseau et al. J Clin Oncol. 2010;28(30): Sonneveld et al. J Clin Onc. 2012;30: % 50-65% Randomized Comparisons % INDUCTION REGIMEN CR VGPR TAD vs 3 37* VAD * VD vs 6 38* VAD 2 1* 15* PAD vs NR 42* VAD 3 NR 15* VTD vs 19* 62* TD 4 5* 28* VTD vs 35* 60* TD 5 14* 29* vtd vs 13* 49* VD 6 12* 36* * P value statistically significant 4. Cavo et al. Lancet 2010;379(9758): Rosiñol et al. Blood Aug 23;120(8): Moreau et al. Blood 2011;118(22):5752-8
6 Different Induction Regimens and Outcome after ASCT 6 Selection of initial regimen appears to impact posttransplant outcome Autotransplant Consolidation Initial therapy Maintenance Post-ASCT response rates further improve for all regimens Depth of response improves also in superior arms Statistical differences between two arms persist* *see for summary of data in supplemental slide Adopted from Cavo et al. Lancet 2010;379(9758):
7 Initial Treatment Strategy and Time to Event 7 TAD + Thal vs 34 mo* 73 mo VAD + IFN 1 22 mo* 60 mo VD+ Len ± Len vs 36 81% (3-yr) VAD+ Len ± Len % (3-yr) PAD + Bort vs 36 mo* HR = 0.73* VAD + Thal 3 27 mo* NR VTD + VTD vs TD + TD 4 Randomized Studies 68% (3-yr)* 86% (3-yr)* 56% (3-yr)* 84% (3-yr)* VTD vs 56 mo* NR TD 5 27 mo* NR vtd vs 26 NR VD 6 30 NR 1. Lokhorst et al. Blood 2010;115(6): Harousseau et al. J Clin Oncol. 2010;28(30): Sonneveld et al. J Clin Onc. 2012;30: Cavo et al. Lancet 2010;379(9758): Rosiñol et al. Blood Aug 23;120(8): Moreau et al. Blood 2011;118(22): VTD vs TD Cavo et al. Blood 2010; 116(21). Abstract 42, Lancet 2011;376(9758): * P value statistically significant
8 Post-Transplant Consolidation and Maintenance 8 Autotransplant Consolidation Initial therapy RVD Benefits of consolidation not established Bortezomib VTD Lenalidomide Lenalidomide PFS prolonged (2/2) OS prolonged (1/2) Bortezomib PFS and OS (1/1) Maintenance Thalidomide PFS prolonged (6/6) OS prolonged (3/6) Placebo Revlimid Attal et al, ASH 2010.sequential approach including a proteasome inhibitor before and after ASCT improves the outcome in transplant-eligible patients Palumbo J Clin Onc 2012; 2012 vol. 30 no
9 New Agents in Initial Treatment of Transplant Candidates 9 Carfilzomib regimens CYCLONE, CRd MLN9708 regimens MLN9708+Rd Initial therapy Autotransplant Consolidation Maintenance Conventional VAD Novel Combinations 2-Drug: TD, VD, RD, Rd 3-Drug/1-Novel: TAD, PAD, VDD, CVD 3-Drug/2-Novel: VTD, RVD 4-Drug/2-Novel: CVDR, VTDC, RVDD
10 Cyclophosphamide, Carfilzomib, Thalidomide, Dexamethasone (CYCLONE) Phase II: Schema 10 Newly Diagnosed MM Carfilzomib (20/27 mg/m 2 IV, days 1,2, 8,9, 15,16) Cyclophosphamide (300 mg/m 2 po, days 1, 8, 15) Thalidomide (100 mg po days 1-28) Dexamethasone (40 mg po days 1, 8, 15, 22) 28-day cycles x4 Response PFS Toxicity Stem cell harvest Mikhael et al, ASCO 2012, Courtesy J. Mikhael
11 CYCLONE Phase II: Efficacy (n=24) patients treated in Phase II Median follow up 8.2 m ( ) CR 7 VGPR 11 PR 5 MR 1 VGPR 75% 29% 46% CR VGPR PR MR > PR 96% 21% Toxicities manageable Extend Phase II with increasing doses of carfilzomib: Target CFZ 45mg/m 2 4% Mikhael et al, ASCO 2012, Courtesy J. Mikhael
12 New Agents in Initial Treatment of non-transplant Candidates 12 MP-based regimens MPT > MP VMP > MP VMP = VTP VMPT-VT > VMP MPR-R>MPR=MP Other regimens e.g. Rd, RVD Elotuzumab +/- Rd Carfilzomib +MP (CMP) Initial therapy Maintenance Continue initial therapy
13 Carfilzomib +MP (CMP): Treatment schedule 13 9 cycles / 42 days Dosing and schedule Carfilzomib C1: D1, D2, Carfilzomib 30 min-iv 20 mg/m²/day D8, D9, D22, D23, D29, D30 Carfilzomib 20, 27, 36 or 45 mg/m²/day (cohort 1, 2, 3, or 4) C2 to C9: Carfilzomib 20, 27, 36 or 45 mg/m²/day (cohort 1, 2, 3, or 4 D1, D2, D8, D9, D22, D23, D29, D30) Melphalan C1-9: PO 9 mg/m²day D1 to D4 Prednisone C1-9: PO 60 mg/m² day D1 to D4 Kolb et al, ASCO 2012, Courtesy P. Moreau
14 CMP: Results patients have been enrolled : Median age 74 years (66 86) EFS MTD defined at 36 mg/m2 80.7% After a median of 8 cycles (1 9): / 35 patients 1 CR > VGPR 40% 14 VGPR ORR: 89% 16 PR 1 MR 2 stable disease 1 progression No neurotoxicity!! (1 grade 1) OS 93.9% Median follow-up: 12 months Kolb et al, ASCO 2012, Courtesy P. Moreau
15 Changing Paradigm of Treatment of Transplant Candidates 15 Initial therapy Transplant Candidates Autotransplant or Continue initial therapy Maintenance Continue initial therapy Non-transplant Candidates
16 Rationale for Delayed Autotransplant in the Era of Novel Regimens 16 RVD Regimen PFS by ASCT status from 1-yr landmark Responses at 4 cycles: PR 75%, > VGPR 11%, CR/nCR 6% Best Response (all patients) > PR 100%, > VGPR 67%, CR/nCR 39% Richardson et al, Blood Aug 5;116(5): Epub 2010 Apr 12 Main limitation of extended RVD treatment peripheral neuropathy Transplant eligible Autotransplant RVD Consolidation RVD vs R Maintenance Continue RVD
17 Frontline MLN Rd Treatment Schema Transplanteligible and - -ineligible patients MLN9708+Rd Induction Cycles 1 3/4 Cycles 4-12/5-16 Transplant-eligible Stem cell collection MLN9708 Maintenance Cycles 13/16+ Until disease progression or unacceptable toxicity ASCT after 6 (weekly) or 8 (twice-weekly) cycles Cycles 1 12 (weekly) or 1-16 (twice-weekly) MLN9708 weekly schedule D 1, 8, 15 in 28-d cycles, twice-weekly schedule D 1, 4, 8, 11 in 21-d cycles 1 LEN 25 mg Days 1 21 (weekly schedule 280day cycles), 1-14 (twice weekly schedule 21-day cycles) DEX 40 mg weekly Cycles 1-12 (weekly), 20/10 mg 1, 2, 4, 5, 8, 9, 11, Cycles 1 8/ 9-12 (twice-weekly) Cycles 12+ (weekly)/16+(twice-weekly) MLN9708 at last best tolerated dose 1 Based on Richardson et al. EHA
18 MLN9708 +Rd: Response Rates Response, % Weekly Schedule Best Response* (n=64) 4+ cycles (n=46) PR Twice-weekly Schedule Response, % Best Response* (n=10) 4+ cycles (n=6) PR VGPR VGPR CR 26 CR *Median 4 cycles (range 1 15) *Median 4 cycles (range 1 8) Response appears to get better with time on treatment Toxicities manageable with rash or fatigue most common; peripheral neuropathy 18-33% 1 Based on Richardson et al. EHA 2012.
19 Frontline CRd Treatment Schema Transplanteligible and - -ineligible patients CRd Induction CRd Cycles 1 4 CRd Cycles 5 8 Transplant-eligible PR ASCT Stem cell collection CRd Maintenance CRd Cycles 9 24 Lenalidomide (off protocol) LEN Cycles 25+ Until disease progression or unacceptable toxicity Assessments on D1 and 15 of C1 and D1 thereafter using modified IMWG Criteria with ncr Cycles 1 8 CFZ mg/m 2 Days 1 2, 8 9, LEN 25 mg Days 1 21 DEX 40 mg weekly Cycles 1-4, 20 mg weekly Cycles 5 8 Jakubowiak AJ, et al. ASCO 2012., Blood 2012; 120(9): Cycles 9 24 CFZ on Days 1 2 and only CFZ, LEN, DEX at last best tolerated doses Cycles 25+ LEN at last best tolerated dose 19
20 Patients (%) Frontline CRd: Best Response Median 12 cycles (range 1 25) PR VGPR ncr scr All patients N=53 There was no difference by disease stage and cytogenetics Jakubowiak AJ, et al. ASCO 2012., Blood 2012; 120(9):
21 M-protein level (% of baseline) Response (%) Frontline CRd Responses at Different Time Points 100 ncr scr M-protein Cycle 0 20/22 patients (91%) with suspected CR had no evidence of MRD by multiparameter flow cytometry 1. Jakubowiak AJ, et al. ASCO
22 Response (%) Frontline CRd Responses after Extended Treatment 100 ncr scr Overall n=53 Median 12 cycles (range 1 25) 4+ Cycles n=49 Median 13 cycles (range 4 25) 8+ Cycles n=36 Median 16 cycles (range 8 25) Jakubowiak AJ, et al. ASCO 2012., Blood 2012; 120(9):
23 Frontline CRd Progression-free Survival 12-month rate 97% 24-month rate 92% Median follow-up of 13 months (range 4-25) 2 patients progressed All patients with scr have maintained response for median 9 months (range 1 20) Jakubowiak AJ, et al. ASCO 2012., Blood 2012; 120(9):
24 Will New Combinations Change a Strategy of Initial Treatment? 24 PRE-TRANSPLANT INDUCTION - Carfilzomib-based regimens (i.e. CYCLON or CRd) appear to provide superior rate of >VGPR than bortezomib +/- IMiD-based regimens - MLN9708+Rd regimen appears promising; awaiting more information on its role in pre-transplant setting - It is still not settled how critical is the choice of specific pretransplant regimen INITIAL THERAPY IN NON-TRANSPLANT CANDIDATES If MP-based regimens are to be used for primary treatment, then CMP (MP + Carfilzomib) is emerging as possibly most active Some of emerging new regimens (e.g. CRd) appear to be more active than any MP-based regimens and show extended tolerability All oral MLN9708+Rd is very active and maybe very appealing to use in non-transplant candidates provided it shows extended tolerability
25 Are new combinations changing the current paradigm of treatment of myeloma? 25 TRANSPLANT AND NON-TRANSPLANT CANDIDATES We can now achieve similar or better results after extended treatment without transplant of both transplant and non-transplant candidates( e.g. CRd) than with bortezomib-based induction, followed by transplant, followed by consolidation and maintenance in transplant candidates FUTURE DIRECTIONS Carfilzomib and MLN9708 will likely find their place in frontline therapy but we need longer follow-up and new data from ongoing and recent studies (including short and long term tolerability) Other agents, e.g. elotuzumab are likely to make further impact on treatment of new myeloma Increased focus on depth of response (scr, MRD) Likely shift to paradigms based on disease subtype-based individualized therapy rather than based on transplant versus non transplant status
26 Additional Slides
27 27 Different Induction Regimens followed by ASCT Induction with 4-drug vs 3-drug regimens Autotransplant Consolidation Initial therapy Maintenance RVD RVDD Induction Post-Transplant Attal et al. Blood ASH 2010/Richardson et al. Blood 2010 Studies not designed for comparison Jakubowiak et al. Blood Epub 2011
28 Different Induction Regimens followed by ASCT 28 Will adding 4 th drug to 3-drug regimen improve outcome? Autotransplant Consolidation Initial therapy Maintenance RVDD? VCRD not better than VRD or CVD After 4 cycles, % >PR >VGPR CR/nCR RVD* RVDD* Richardson et al., Blood 2010 Jakubowiak et al., Blood 2011 *Studies not designed for comparison
29 Is there are Role for Consolidation after ASCT? 29 Autotransplant Consolidation Initial therapy % post- ASCT % post- Consolidation REGIMEN CR VGPR CR VGPR Bortezomib vs * 71* observation * 57* VTD vs 55 NR 62* NR TD 2 41 NR 45 NR Len * 67* Bortezomib VTD vs TD Lenalidomide Depth of response improves MRD rates improve Maintenance 1. Mellqvist et al. Haematologica 2011; 96(suppl 1). Abstract Cavo et al. Blood 2010;116(21). Abstract Attal et al. Blood 2009;114(22). Abstract 529. Terragna et al. Blood 2010; 116(21). Abstract 861
30 Patients (%) Maintenance in non-transplant candidates 30 MPR Landmark Analysis 69% Reduced Risk of Progression Lenalidomide Continuous Therapy HR P <.001 MPR-R MPR Lenalidomide PFS improved MPR-R > MPR Bortezomib-based VMPT-VT > VMP VT > VP? Cycle 10 Time (months) Initial therapy 1 Maintenance Continue initial therapy 1. Palumbo et al, Blood 2010 (21); Abstract Palumbo et al, Blood 2010; 116(21) Abstract Mateos et al. Lancet Oncology; 2010 Oct;11(10): Epub 2010 Aug 23
31 CYCLON: Results patients treated in Phase II 4 sites: Mayo Arizona, Mayo Rochester, University of New Mexico and Medical University of South Carolina Median follow up 8.2 mths ( ) 26/27 are still alive Pt died during cycle 3, felt to be unrelated to therapy Only one other pt elected to be removed from study Mikhael et al, ASCO 2012, Courtesy J. Mikhael
32 Carfilzomib + MP (CMP): Rationale 32 - MP + bortezomib, «VMP», is one of the standard of care in the treatment of patients with symptomatic myeloma not eligible for high-dose therapy - VMP (Vista) : 14% grade 3 / 4 peripheral neuropathy 71% Overall response rate - Carfilzomib: second-in-class proteasome inhibitor, without neurotoxicity, high response rate in relapsed/refractory MM - Carfilzomib MP: effective combination regimen in elderly patients? Kolb et al, ASCO 2012, Courtesy P. Moreau
33 33 CMP: Toxicity AE grade > 3 DVT : 6% Renal impairment: 3% Infections: 15% Pericardial effusion: 3% Fatigue: 3% Atrial fibrillation: 6% Cardiac failure: 3% Toxic death: 3% No neurotoxicity!! (1 grade 1) Kolb et al, ASCO 2012, Courtesy P. Moreau
34 MLN Rd: Study design Study Induction MLN9708 Lenalidomide Dexamethasone Weekly D 1, 8, mg, D 1 21 Up to 12 x 28-day cycles Twice-weekly D 1, 4, 8, mg, D 1 14 Up to 16 x 21-day cycles 40 mg, D 1, 8, 15, 22 20/10 mg (cycles 1 8/9 16), D 1, 2, 4, 5, 8, 9, 11, 12 MLN9708 maintenanc e D 1, 8, day cycles D 1, 4, 8, day cycles Phase 1: oral MLN9708 dose-escalation Standard 3+3 schema, 33% dose increments, based on cycle 1 DLTs Phase 2: oral MLN9708 at the RP2D from phase 1 Each protocol allows for stem cell collection after cycles 3 / 4, with autologous stem cell transplantation (ASCT) deferred until after 6 / 8 cycles in the weekly / twice-weekly studies, respectively MLN9708 maintenance continued until progression or unacceptable toxicity Richardson et al, EHA 2012, Courtesy P. Richardson
35 MLN9708 +Rd Drug-related* AEs, all grades ( 10% of total) in weekly dosing study AE, n (%) Phase 1 (n=15) Phase 2 (n=50) Total (n=65) Rash 6 (40) 17 (34) 23 (35) Fatigue 5 (33) 16 (32) 21 (32) Nausea 6 (40) 14 (28) 20 (31) Vomiting 7 (47) 9 (18) 16 (25) Thrombocytopenia 5 (33) 10 (20) 15 (23) Constipation 3 (20) 12 (24) 15 (23) Peripheral neuropathies 5 (33) 9 (18) 14 (22) Diarrhea 7 (47) 6 (12) 13 (20) Anemia 2 (13) 7 (14) 9 (14) Peripheral edema 2 (13) 6 (12) 8 (12) Muscle spasms 3 (20) 5 (10) 8 (12) Insomnia 2 (13) 6 (12) 8 (12) Dysgeusia 1 (7) 7 (14) 8 (12) Neutropenia 1 (7) 6 (12) 7 (11) Dizziness 4 (27) 3 (6) 7 (11) *Drug-related defined as related to any drug in the study drug combination, not specifically related to MLN9708 Pruritic, papular, maculo-papular, macular, erythematous, rash Includes peripheral neuropathy and peripheral sensory neuropathy Richardson et al, EHA 2012, Courtesy P. Richardson
36 Drug-related* AEs, grade 3 ( 2 pts overall) in weekly-dosing study AE, n (%) Phase 1 (n=15) Phase 2 (n=50) Total (n=65) Any grade 3 / 4 / 5 AE, % 60 / 0 / 0 30 / 2 / 2 37 / 1.5 / 1.5 Rash 2 (13) 5 (10) 7 (11) Blood and lymphatic system disorders 2 (13) 2 (4) 4 (6) Lymphopenia 1 (7) 1 (2) 2 (3) Thrombocytopenia 1 (7) 1 (2) 2 (3) Vomiting 3 (20) 0 3 (5) Nausea 2 (13) 1 (2) 3 (5) Syncope 2 (13) 0 2 (3) Fatigue 0 2 (4) 2 (3) One pt treated 2 dose levels above RP2D experienced grade 3 peripheral neuropathy with weekly MLN9708 in combination with lenalidomide and lowdose dexamethasone No grade 4 peripheral neuropathy *Drug-related defined as related to any drug in the study drug combination, not specifically related to MLN9708 Pruritic, papular, maculo-papular, macular, erythematous, rash Richardson et al, EHA 2012, Courtesy P. Richardson
37 Drug-related* AEs in twice-weekly dosing study AE n, % (N=11) All grades ( 10% pts) Fatigue 8 (73) Rash 7 (64) Constipation 3 (27) Insomnia 3 (27) Peripheral edema 2 (18) Anemia 2 (18) Peripheral neuropathies 2 (18) Tremor 2 (18) Hyperglycemia 2 (18) Hiccups 2 (18) Any grade 3 / 4 4 (11) / 0 Grade 3 ( 2 pts) Hyperglycemia 2 (18) *Drug-related defined as related to any drug in the study drug combination, not specifically related to MLN9708 Includes rash, rash maculo-papular, rash macular, rash pruritic, urticaria Includes peripheral neuropathy and peripheral sensory neuropathy; no grade 3/4 peripheral neuropathy Richardson et al, EHA 2012, Courtesy P. Richardson
38 MLN9708 +Rd Preliminary response in weekly-dosing study 64 of 65 pts received 1 cycle of treatment, and therefore were evaluable for response (response not confirmed by second assessment) 15 in phase 1, 49 in phase 2 Received median 4 cycles (range 1 15) Phase 1: median 6 (1 15), phase 2: median 3 (1 5) ORR: 91% 100% in phase 1, 88% in phase 2 CR+VGPR rate: 39% 53% in phase 1, 35% in phase 2 Richardson et al, EHA 2012, Courtesy P. Richardson
39 CRd Extended Treatment Tolerability 29 patients continue CRd maintenance (cycles 9 24) 5 pts patients initiated maintenance with single-agent lenalidomide (cycles 25+) Most common toxicities during maintenance were lymphopenia (30%), leukopenia (26%), and fatigue (25%) Limited dose modifications: 19% CFZ, 28% Len, and 31% Dex No discontinuations due to toxicity during maintenance phase Limited peripheral neuropathy (11%, all grade 1/2) No treatment related deaths during induction or maintenance Jakubowiak et al, ASCO 2012, Blood 2012; 120(9):
CME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationMillennium Pharmaceuticals, Inc., Cambridge, MA; 11 Dana-Farber Cancer Institute, Boston, MA
Phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma Shaji K. Kumar,
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationPhase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationIn the previous decade, younger patients with newly diagnosed
MYELOMA TREATMENT UPDATE Update on the Initial Therapy of Multiple Myeloma Donna Reece, MD OVERVIEW Advances in myeloma biology and the identification of new anti-myeloma agents have resulted in improved
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationLong-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone
Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma (MM): Phase 2 study
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationMultiple Myeloma: Update from ASH. Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School
Multiple Myeloma: Update from ASH Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School Integration of Novel Therapy Into Myeloma Management
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationAt Fox Chase Cancer Centre during study participation
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor Ixazomib at the Recommended Phase 3 Dose in Patients with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationPlasma cells in bone marrow. Treatment of Multiple Myeloma Novel Approaches. Approach to Progressive MM. Approach to Initial Therapy
Treatment of Multiple Myeloma ovel Approaches Plasma cells in bone marrow Donna E. Reece, M.D. Princess Margaret Hospital Toronto, 21 ctober 25 Adhesion Molecules and Growth Factors in Multiple Myeloma
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationRegimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More information